Signaling networks associated with BCR-ABL-dependent transformation
- PMID: 19337196
- DOI: 10.1177/107327480901600202
Signaling networks associated with BCR-ABL-dependent transformation
Abstract
Background: The fusion protein BCR-ABL results in constitutive tyrosine kinase activity. It also affects downstream targets as well as the subcellular location of the normally tightly regulated Abl tyrosine kinase.
Methods: The authors review the current knowledge concerning the signaling networks associated with BCR-ABL-dependent transformation.
Results: Although BCR-ABL is considered a single genetic change, the dysregulated tyrosine kinase activates a network of signals that contributes to cytokine-independent growth, resistance to apoptosis, and genetic instability.
Conclusions: The effectiveness of BCR-ABL-dependent transformation of hematopoietic stem cells is due not to a single pathway but rather to the culmination of a network of signaling pathways.
Similar articles
-
Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21. Oncogene. 2008. PMID: 18427551
-
Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene.Cell. 1995 Sep 22;82(6):981-8. doi: 10.1016/0092-8674(95)90277-5. Cell. 1995. PMID: 7553858
-
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.Oncogene. 2002 Nov 21;21(53):8075-88. doi: 10.1038/sj.onc.1206008. Oncogene. 2002. PMID: 12444544
-
Molecular mechanisms of transformation by the BCR-ABL oncogene.Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10. doi: 10.1053/shem.2003.50034. Semin Hematol. 2003. PMID: 12783368 Review.
-
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1. Mol Diagn Ther. 2016. PMID: 27220498 Review.
Cited by
-
Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line.Invest New Drugs. 2011 Oct;29(5):827-32. doi: 10.1007/s10637-010-9430-6. Epub 2010 Apr 27. Invest New Drugs. 2011. PMID: 20422253
-
Assessment of interleukin 1β serum level in different responder groups and stages of chronic myeloid leukemia patients on imatinb mesylate therapy.Indian J Hematol Blood Transfus. 2014 Dec;30(4):247-52. doi: 10.1007/s12288-014-0339-7. Epub 2014 Feb 7. Indian J Hematol Blood Transfus. 2014. PMID: 25435722 Free PMC article.
-
Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia.PLoS One. 2014 Jun 26;9(6):e100960. doi: 10.1371/journal.pone.0100960. eCollection 2014. PLoS One. 2014. PMID: 24968304 Free PMC article.
-
FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5.Int J Mol Sci. 2024 Mar 26;25(7):3693. doi: 10.3390/ijms25073693. Int J Mol Sci. 2024. PMID: 38612503 Free PMC article.
-
Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.Cell Commun Signal. 2021 Jul 3;19(1):71. doi: 10.1186/s12964-021-00752-9. Cell Commun Signal. 2021. PMID: 34217296 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous